Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Jeremy S. Abramson, MD, MMSc, discusses highlights of the key data from ASH 2020 on the treatment of patients with lymphomas/CLL, with topics including:
Jeremy S. Abramson, MD, MMSc
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Downloadable slideset from a local live webinar developed by lymphoma experts with guidance on the management of indolent lymphomas
Experts highlight key studies presented at the 2022 EHA annual meeting in this commentary from Clinical Care Options (CCO)
Slides from Clinical Care Options (CCO) with key findings on BTK inhibitors in CLL and MCL from the 2022 ASCO, EHA, Pan Pacific, ESMO, and SOHO meetings
Phase II trial shows high response rates and high 3-year EFS and OS rates with crenolanib plus 7+3 chemotherapy in newly diagnosed FLT3-mutated AML, presented at ASCO 2022 and reported by Clinical Care Options (CCO)